Evidence map›Paper›PMID 42361041›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Collagen-producing eye cell atlas reveals distinct fibroblast fates in early injury vs. fibrotic subretinal disease.

Ema Ozaki, Said Aktas, Kelly Mulfaul, Kiva Brennan, Christophe Roubeix, Sarah Palko, Katie Robb, Tai-Hsien Ou Yang, Marie-Claire Schanne-Klein, Anna Toidze and 5 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Collagen-producing eye cell atlas reveals distinct fibroblast fates in early injury vs. fibrotic subretinal disease.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ema OzakiDepartment of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.
Said AktasPharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG., Schlieren 8952, Switzerland.ORCID 0009-0002-2396-3750
Kelly MulfaulDepartment of Neuroscience and Pharmacology, University of Iowa, Iowa City, IA 52242-1109.
Kiva BrennanDepartment of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.
Christophe RoubeixRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4058 Basel, Switzerland.
Sarah PalkoDepartment of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.
Katie RobbDepartment of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.
Tai-Hsien Ou YangRoche Pharma Research and Early Development, Data and Analytics, Roche Translational & Clinical Research Center, F. Hoffmann-La Roche Ltd., Little Falls, NJ 07424.
Marie-Claire Schanne-KleinLaboratoire d'Optique et Biosciences, Ecole Polytechnique, CNRS, INSERM, Institut Polytechnique de Paris, Palaiseau 91120, France.ORCID 0000-0003-3026-8932
Anna ToidzeRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4058 Basel, Switzerland.
Avril WatsonDepartment of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.ORCID 0000-0001-5533-687X
Mark CahillProgressive Vision Research, Dublin 18, Ireland.
Peter D WestenskowRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4058 Basel, Switzerland.ORCID 0000-0001-9841-6220
Derrick FeenstraRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4058 Basel, Switzerland.
Sarah L DoyleDepartment of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.ORCID 0000-0002-6294-9380

Funding

BrightFocus Foundation (BFF) M2023011F. Hoffmann-La Roche Immunolgy incubator programmeScience Foundation Ireland (SFI) SFI 21/SPP/3732
6 · The paper itself

Abstract

Fibrosis is the end-stage of a maladaptive process that occurs when the body's normal wound-healing strategy becomes dysregulated. Subretinal fibrosis is the end stage of neovascular age-related macular degeneration (nAMD), the most common cause of central vision loss in people over the age of 50. The cellular sources of excess extracellular matrix (ECM) contributing to subretinal fibrosis are unknown, as is the heterogeneity of cells involved in the fibrotic process. Here we identify cells contributing to subretinal fibrosis by using

Indexed as

CollagenFibroblastsMacular DegenerationRetinaAnimalsCell Adhesion MoleculesCollagen Type IDisease Models, AnimalExtracellular MatrixFibrosisHumansMicePeriostinCell Adhesion MoleculesCollagenCollagen Type IPeriostinPostn protein, mousecollagen-atlasfibroblastneovascular age-related macular degenerationscRNA-sequencingsubretinal fibrosis

Identifiers

PMID42361041
PMCPMC13320955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.